News Daily News Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths Michael O'Riordan December 08, 2022
News Conference News HFSA 2022 New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented Todd Neale October 07, 2022
News Conference News HFSA 2022 Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER Todd Neale October 04, 2022
News Conference News ESC 2022 DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum Todd Neale August 27, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
News Daily News Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis Caitlin E. Cox May 03, 2022
News Daily News Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse Todd Neale January 21, 2022
News Daily News As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control Caitlin E. Cox January 10, 2022